Managing Editor, In Vivo
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Gilead Raday, chief operating officer of RedHill Biopharma, talks to Lucie Ellis, executive editor of In Vivo, about recently published late-stage data and next steps for its antibiotic asset, Talicia (RHB-105), for the treatment of Helicobacter pylori infection.
At the recent BIO-Europe Spring partnering conference, Tim Dyer, CEO of Addex Therapeutics, spoke to Lucie Ellis, executive editor of In Vivo, about the company’s small-molecule allosteric modulators for central nervous system disorders.
Roel Bulthuis, managing partner of INKEF Capital, talks to In Vivo’s executive editor Lucie Ellis about the group’s €500m fund and where INKEF is placing its bets in biotech.
As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.
Peter Llewellyn-Davies, CEO and chief financial officer of Apeiron Biologics, talks to Lucie Ellis, executive editor of In Vivo, on the sidelines of the recent BIO-Europe Spring conference about the company’s pipeline and partnering strategy.
Jonas Renz, managing director of antisense platform company Secarna, discussed deal making and the company’s outlook in an interview at the recent BIO-Europe Spring partnering conference.